Astrazeneca wins wider US approval for Lynparza ovarian cancer drug

By |2017-10-26T01:18:38+00:00August 18th, 2017|Categories: Ovarian Cancer News and Research|

This is a PARP Inhibitor for maintenance treatment for women with platinum-sensitive recurrent, epithelial ovarian, fallopian tube or primary peritoneal adult cancer, regardless of their BRCA status.

AstraZeneca and Merck have been given approval by the US drug administrator to sell their olaparib ovarian cancer drug, branded Lynparza, in a new tablet form and to a wider range of cancer sufferers.

The US Food and Drug Administration granted approval for the drug, which is a PARP inhibitor, meaning it stops the actions of the poly ADP-ribose polymerase protein that helps damaged cells to repair themselves.

Read the full story here: https://www.digitallook.com/news/news-and-announcements/astrazeneca-wins-wider-us-approval-for-lynparza-ovarian-cancer-drug–2820231.html

%d bloggers like this: